Publication date: Available online 15 October 2026 Source: The Lancet Infectious Diseases Author(s): Shilpi Jain, Laura Morgan, Mary Choi, Jason Malenfant, Shannon L M Whitmer, Enogo Koivogui, Nouonan Gbamou, Siba Michel Grovogui, Boubacar Diallo, Salomon Corvil, Trevor Shoemaker, Stephen Balinandi, Joel M Montgomery, Christina F Spiropoulou, César G Albariño, Éric Bergeron
Cross-neutralisation of authentic Ebola virus and Bundibugyo virus following natural infection or Ervebo vaccination. // The Lancet Infectious Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S147330992600544X?dgcid=rss_sd_all
Cross-neutralisation of authentic Ebola virus and Bundibugyo virus following natural infection or Ervebo vaccination. The Lancet Infectious Diseases. https://www.sciencedirect.com/science/article/pii/S147330992600544X?dgcid=rss_sd_all
“Cross-neutralisation of authentic Ebola virus and Bundibugyo virus following natural infection or Ervebo vaccination.” The Lancet Infectious Diseases.
@article{article68909,
title = {Cross-neutralisation of authentic Ebola virus and Bundibugyo virus following natural infection or Ervebo vaccination},
journal = {The Lancet Infectious Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S147330992600544X?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...